tiprankstipranks
OKYO Pharma Begins Key Trial for Eye Pain Therapy
Company Announcements

OKYO Pharma Begins Key Trial for Eye Pain Therapy

OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.

Pick the best stocks and maximize your portfolio:

OKYO Pharma Limited has initiated its first Phase 2 clinical trial for OK-101, a novel non-opioid treatment designed to address neuropathic corneal pain, a condition lacking FDA-approved therapies. The trial, involving 48 patients, aims to explore the safety and efficacy of OK-101, potentially offering a breakthrough for patients suffering from the debilitating effects of corneal nerve damage. With this step, OKYO Pharma takes a significant move towards providing a much-needed therapeutic option in ophthalmology.

For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskOKYO Pharma to Highlight Innovations at BTIG Conference
TipRanks Auto-Generated NewsdeskOKYO Pharma Advances in Ocular Treatment Trials
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App